Stallergenes Greer: Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment on the Onset and Worsening of Asthma in Patients With Allergic Rhinitis

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study. Presented at the 2022 European Academy

Related Keywords

France ,Czech Republic ,Frolund ,Midtjylland ,Denmark ,United States ,Paris ,France General ,Copenhagen ,Køavn ,Switzerland ,Czech ,French ,Henrik Nielsen ,Michele Antonelli ,Catherine Kress ,Pascal Demoly ,Philippe Devillier ,Bertrand Delaisi ,Mathieu Molimard ,Stallergenes Greer ,Jean Fran ,World Health Organization ,Stallergenes Greer International ,Diderot University France ,Montpellier University Hospital France ,European Academy Of Allergy ,Greer Laboratories Inc ,Thoracic Oncology Department ,Clinical Immunology ,Professor Pascal Demoly ,Montpellier University Hospital ,Chief Executive Officer ,Internal Medicine ,Paris Diderot University ,Greer International ,Greer Laboratories ,Allergy Clin ,Copenhagen Allergy ,Shinj W ,Suej H ,Songt W ,Allergy Asthma ,Stallergenes ,Career ,Positive ,Results ,Fficapsi ,Meal ,World ,Study ,Confirm ,Significant ,Benefit ,Sublingual ,Liquid ,Treatment ,Onset ,Worsening ,Asthma ,Patients ,Ith ,Aallergic ,Rhinitis ,